Chao-kuei Juan
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Drug persistence of omalizumab, cyclosporine, and hydroxychloroquine in antihistamine-refractory chronic spontaneous urticaria: A biomarker-stratified real-world study.
Journal: Asian Pacific journal of allergy and immunology
Published: July 29, 2026
Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study.
Journal: Clinical pharmacology and therapeutics
Published: October 24, 2025
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.
Journal: JAMA dermatology
Published: June 18, 2025
Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents.
Journal: Rheumatology (Oxford, England)
Published: March 15, 2025
Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study.
Journal: PLoS medicine
Published: November 05, 2024
Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis: A population-based cohort study.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: September 03, 2024
Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
Journal: Journal of the American Academy of Dermatology
Published: November 15, 2023
Fracture risks in patients with atopic dermatitis: A nationwide matched cohort study.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: July 27, 2021
Ultrasound-aided diagnosis of preclinical phases of psoriatic arthritis in biologic-naïve psoriasis patients with or without arthralgia.
Journal: Clinical and experimental rheumatology
Published: January 30, 2021
Long-Term Risk of Autoimmune Diseases other than Systemic Lupus Erythematosus in Cutaneous Lupus Erythematosus-Alone Patients: A 10-Year Nationwide Cohort Study.
Journal: Dermatology (Basel, Switzerland)
Published: November 22, 2020
Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study.
Journal: The Journal of dermatology
Published: July 12, 2020
Last Updated: 09/26/2026